Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study).
Calegari MA, Salvatore L, Di Stefano B, Basso M, Orlandi A, Boccaccino A, Lombardo F, Auriemma A, Zurlo IV, Bensi M, Camarda F, Ribelli M, Vivolo R, Cocomazzi A, Pozzo C, Milella M, Martini M, Bria E, Tortora G. Calegari MA, et al. Among authors: camarda f. Cancers (Basel). 2021 Apr 27;13(9):2098. doi: 10.3390/cancers13092098. Cancers (Basel). 2021. PMID: 33925278 Free PMC article.
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, Gori S, Tonini G, Barone C. Calegari MA, et al. Among authors: camarda f. Br J Cancer. 2017 May 9;116(10):1279-1286. doi: 10.1038/bjc.2017.109. Epub 2017 Apr 20. Br J Cancer. 2017. PMID: 28427088 Free PMC article. Clinical Trial.
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Parisi A, et al. Among authors: camarda f. Cancers (Basel). 2020 May 16;12(5):1259. doi: 10.3390/cancers12051259. Cancers (Basel). 2020. PMID: 32429380 Free PMC article.
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report.
Calegari MA, Stefano BD, Basso M, Carbone C, Camarda F, Ribelli M, Anghelone A, Vivolo R, Bensi M, Martini M, Pozzo C, Vellone M, Ardito F, Salvatore L, Giuliante F, Tortora G. Calegari MA, et al. Among authors: camarda f. Clin Colorectal Cancer. 2021 Dec;20(4):364-367. doi: 10.1016/j.clcc.2021.09.002. Epub 2021 Sep 15. Clin Colorectal Cancer. 2021. PMID: 34629317 No abstract available.
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Among authors: camarda f. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Management of single pulmonary metastases from colorectal cancer: State of the art.
Chiappetta M, Salvatore L, Congedo MT, Bensi M, De Luca V, Petracca Ciavarella L, Camarda F, Evangelista J, Valentini V, Tortora G, Margaritora S, Lococo F. Chiappetta M, et al. Among authors: camarda f. World J Gastrointest Oncol. 2022 Apr 15;14(4):820-832. doi: 10.4251/wjgo.v14.i4.820. World J Gastrointest Oncol. 2022. PMID: 35582100 Free PMC article. Review.
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Musacchio L, Valsecchi AA, Salutari V, Valabrega G, Camarda F, Tuninetti V, Giannone G, Bartoletti M, Marchetti C, Pignata S, Fagotti A, Scambia G, Di Maio M, Lorusso D. Musacchio L, et al. Among authors: camarda f. Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24. Cancer Treat Rev. 2022. PMID: 36063572 Review.
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
Musacchio L, Boccia S, Marchetti C, Minucci A, Camarda F, Cassani C, Ventriglia J, Salutari V, Ghizzoni V, Giudice E, Perri MT, Carbone MV, Ricci C, Pignata S, Fagotti A, Scambia G, Lorusso D. Musacchio L, et al. Among authors: camarda f. Int J Gynecol Cancer. 2023 Jun 5;33(6):922-928. doi: 10.1136/ijgc-2022-003903. Int J Gynecol Cancer. 2023. PMID: 36759000
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
Agostinelli V, Musacchio L, Camarda F, Salutari V, Carbone MV, Ghizzoni V, Nero C, Ricci C, Perri MT, Giudice E, Lardino S, Berardi R, Scambia G, Lorusso D. Agostinelli V, et al. Among authors: camarda f. Cancer Manag Res. 2023 Sep 27;15:1063-1072. doi: 10.2147/CMAR.S294080. eCollection 2023. Cancer Manag Res. 2023. PMID: 37790898 Free PMC article. Review.
29 results